Descriptive analysis of pharmacy services provided after community pharmacy screening

[1]  J. Healey,et al.  Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. , 2017, CMAJ open.

[2]  J. Healey,et al.  High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme , 2016, Open Heart.

[3]  V. Rac,et al.  Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario , 2016, BMC Health Services Research.

[4]  V. Rac,et al.  Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013 , 2016, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[5]  L. Weinrauch,et al.  Screening for Type 2 Diabetes Mellitus , 2015, Annals of Internal Medicine.

[6]  Mary Jordan Samuel.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[7]  Paulina Stehlik,et al.  Pharmacy Practice in Australia. , 2015, The Canadian journal of hospital pharmacy.

[8]  D. Prabhakaran,et al.  Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. , 2015, Global heart.

[9]  Nicole Brandt,et al.  Prevalence of Potentially Inappropriate Medication Use in Older Adults Using the 2012 Beers Criteria , 2015, Journal of the American Geriatrics Society.

[10]  L. Dolovich,et al.  Initial uptake of the Ontario Pharmacy Smoking Cessation Program , 2015, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[11]  Stuart W. Turner,et al.  Economic Evaluations of Clinical Pharmacy Services: 2001–2005 , 2009, Pharmacotherapy.

[12]  Deborah V. Kelly,et al.  Patient attitudes regarding the role of the pharmacist and interest in expanded pharmacist services , 2014, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[13]  C. Teljeur,et al.  Effectiveness of systematic screening for the detection of atrial fibrillation (Review) , 2016 .

[14]  S. Greenberg.  American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012, Journal of the American Geriatrics Society.

[15]  C. Campanelli.  American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012 .

[16]  Hude Quan,et al.  Diagnosed hypertension in Canada: incidence, prevalence and associated mortality , 2012, Canadian Medical Association Journal.

[17]  Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.

[18]  L. Chambers,et al.  Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.

[19]  Justin Feigelman,et al.  Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis , 2010, The Lancet.

[20]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[21]  J. Hoffman,et al.  Economic Evaluations of Clinical Pharmacy Services: 2001–2005 , 2009, Pharmacotherapy.

[22]  P. Noyce,et al.  Determinants of the uptake of medicines use reviews (MURs) by community pharmacies in England: a multi-method study. , 2008, Health policy.

[23]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[24]  Nicola J Cooper,et al.  Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis , 2008, BMJ : British Medical Journal.

[25]  Andrew D Cowley,et al.  Watch out for Wii shoulder , 2008, BMJ : British Medical Journal.

[26]  J Raftery,et al.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. , 2005, Health technology assessment.

[27]  M Sculpher,et al.  Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.

[28]  Stephen W. Sorensen,et al.  Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis , 2004, Annals of Internal Medicine.

[29]  B. Alpert.  Validation of the Pharma-Smart PS-2000 public use blood pressure monitor , 2004, Blood pressure monitoring.

[30]  C. Bond,et al.  Practice‐based pharmaceutical services: a systematic review , 2002 .

[31]  G. Schumock,et al.  Economic Evaluations of Clinical Pharmacy Services—1988–1995 , 1996, Pharmacotherapy.

[32]  A Laupacis,et al.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. , 1995, Archives of internal medicine.

[33]  J. Kaczorowski,et al.  Development of the CANRISK questionnaire to screen for prediabetes and undiagnosed type 2 diabetes , 2009 .

[34]  N. P. Napalkov,et al.  for the prevention and control of noncommunicable diseases , 1999 .

[35]  A. J. Hogan,et al.  Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. , 1995, Progress in cardiovascular diseases.